
IMNN Earnings
Imunon Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Imunon Inc(IMNN) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Imunon Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency:
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-08-05 | Pre-Market | -3.55 | -2.15 | +39.44 | - | - | - | -4.78 | -10.25 |
FY2025Q1 | 2025-05-12 | Pre-Market | -0.35 | -0.28 | +20.00 | - | 0.00 | - | +1.99 | -29.80 |
FY2024Q4 | 2025-02-27 | Pre-Market | -0.36 | -0.23 | +36.11 | - | 0.00 | - | +0.67 | +9.37 |
FY2024Q2 | 2024-08-14 | Pre-Market | -0.55 | -0.51 | +7.27 | - | - | - | -11.11 | +14.81 |
FY2024Q1 | 2024-05-13 | - | -0.57 | -0.52 | +8.77 | - | - | - | +7.25 | +1.45 |
FY2023Q4 | 2024-03-28 | - | -0.59 | -0.52 | +11.86 | - | - | - | +17.14 | -0.71 |
FY2023Q3 | 2023-11-14 | - | -0.66 | -0.37 | +43.94 | - | - | - | -4.04 | -6.06 |
FY2023Q2 | 2023-08-10 | - | -0.71 | -0.61 | +14.08 | - | - | - | -3.20 | -5.60 |
- | 2023-05-11 | - | -0.69 | -0.68 | +1.45 | - | - | - | -5.19 | -2.22 |
- | 2023-03-30 | - | -0.80 | -0.64 | +20.00 | - | - | - | -2.31 | -10.77 |
IMNN Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Imunon Inc reported performance for FY2025Q2, announced on 2025-08-05. The company achieved an EPS of -2.15, compared to analyst estimates of -3.55 by 39.44% . Revenue for the quarter reached 0.00 compared to expectations of 0.00 by % .
The stock price reacted with a -4.78% one-day change and a -10.25% five-day change following the earnings release. These movements reflect market reaction in Imunon Inc growth trajectory and strategic initiatives.
IMNN Earnings Forecast
Looking ahead, Imunon Inc(IMNN) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for have been Go Down by -35.79%, while EPS estimates have been No Change by %. For the upcoming , revenue estimates have been adjusted No Change by % . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Imunon Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between IMNN's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Stock Price
Go Down

-35.79%
In Past 3 Month
1Y
3Y
5Y
Fiscal Period
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price6.70
IMNN Revenue and EPS Performance: A Historical Perspective
Imunon Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-05,Pre-Market):
EPS: -2.15 (Actual) vs.-3.55 (Estimate) (39.44%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: -4.78%(1-Day), -10.25%(5-Day)
FY2025Q1 (2025-05-12,Pre-Market):
EPS: -0.28 (Actual) vs.-0.35 (Estimate) (20.00%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 1.99%(1-Day), -29.80%(5-Day)
FY2024Q4 (2025-02-27,Pre-Market):
EPS: -0.23 (Actual) vs.-0.36 (Estimate) (36.11%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 0.67%(1-Day), 9.37%(5-Day)
Earnings Reaction
The chart below shows how IMNN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IMNN sees a +1.28% change in stock price 10 days leading up to the earnings, and a +15.79% change 10 days following the report. On the earnings day itself, the stock moves by -0.34%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -6.22% on the day following the earnings release and then changed by -12.04% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Imunon Inc (IMNN) Q2 2025 Earnings Call Summary
Neutral
2025-08-05
The earnings call summary presents mixed signals. Financial performance shows improvement with reduced net loss and expenses, but cash position remains weak. The Q&A section reveals optimism about clinical trials and patient demand but lacks concrete partnership details. The stock dividend is a positive move, yet competitive pressures and clinical trial risks persist. Given the absence of strong catalysts or negative shocks, the stock is likely to remain stable in the short term, leading to a neutral sentiment.
Imunon Inc (IMNN) Q1 2025 Earnings Call Summary
Negative
2025-05-12
The earnings call summary and Q&A reveal several concerns: financing risks, competition, and economic factors affecting operations. While there is a focus on partnerships and a decrease in R&D costs, the cash position is weak, and net losses continue. The management's lack of clear responses in the Q&A section exacerbates uncertainty. Despite some cost improvements, these factors suggest a negative stock price reaction over the next two weeks.
Imunon Inc (IMNN) Q4 2024 Earnings Call Summary
Negative
2025-02-27
The earnings call reveals financial and competitive challenges, including a significant net loss and cash constraints, raising concerns about operational sustainability. The Q&A highlights uncertainties in clinical trial success and regulatory approvals, with management providing vague responses to key questions. Although there are strategic plans for Phase 3 trials and potential partnerships, the financial health and clinical risks overshadow positive developments. Given these factors, a negative stock price reaction is anticipated.
Imunon, Inc. (IMNN) Q3 2024 Earnings Call Summary
Neutral
2024-11-07
The earnings call summary presents mixed insights. Basic financial performance shows improvement in net loss and reduced operating expenses, but a decrease in cash position and rising R&D expenses raise concerns. Product development and market strategy are promising with ongoing trials and potential FDA meetings, but uncertainties in partnerships and funding remain. The Q&A section reveals cautious optimism but highlights financial and operational risks. Overall, the lack of clear positive catalysts, combined with financial and operational risks, suggests a neutral sentiment. The market cap is not provided, limiting the prediction of stock price movement intensity.
Imunon, Inc. (IMNN) Q2 2024 Earnings Call Summary
Neutral
2024-08-14
Basic Financial Performance: 3 (Improved losses and expenses but no significant revenue growth). Product Development and Business Update: 4 (Positive progress in clinical trials and partnerships). Market Strategy: 3 (Unclear responses on partnerships). Expenses and Financial Health: 3 (Improved cash position but concerns about financing future trials). Shareholder Return Plan: 3 (No significant announcements). Overall, the sentiment is neutral as positive clinical developments and improved financials are offset by uncertainties in partnerships and future financing.
People Also Watch

BSLK
Bolt Projects Holdings Inc
14.320
USD
+556.88%

MTR
Mesa Royalty Trust
5.680
USD
-3.07%

GNS
Genius Group Ltd
0.893
USD
-5.30%

RYDE
Ryde Group Ltd
0.310
USD
+3.68%

EEIQ
EpicQuest Education Group International Ltd
0.560
USD
-2.95%

BNRG
Brenmiller Energy Ltd
2.000
USD
+10.50%

PET
Wag! Group Co
0
USD
-149.25%

LICN
Lichen International Ltd
4.300
USD
+3.02%
FAQ

What were the key highlights of IMNN’s latest earnings report for FY2025Q2?
IMNN reported its FY2025Q2 earnings on 2025-08-05, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -2.15, surpassing the expected -3.55 by 39.44% . The stock experienced a -4.78% price change on the earnings day and a -10.25% change over the next five days, reflecting market reactions to the results.

How did IMNN’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for IMNN for undefined?

How does IMNN’s stock price correlate with earnings forecast revisions?

What should investors expect from IMNN’s next earnings report?
